MAPTプロトコル:大腿骨頸部骨折後の早期回復のための固定術と人工関節置換術の比較(FASTER-HIP) (FASTER-HIP)
筋骨格適応型プラットフォーム試験(MAPT):股関節骨折後の早期回復のための固定術と関節形成術の外科的治療(FASTER-HIP)
This study is an intervention domain of the Musculoskeletal Adaptive Platform Trial. The primary goal of this pragmatic, randomized, open-label, comparative effectiveness trial is to evaluate if arthroplasty is superior to internal fixation when used to treat minimally displaced femoral neck fractures in older adults ≥60 years old. We hypothesize that arthroplasty will reduce death, preserve ambulation, increase days alive and out of hospital, and improve health status compared to internal fixation within 4 months and 12 months from randomization.
調査の概要
詳細な説明
The Musculoskeletal Adaptive Platform Trial (MAPT) is an adaptive platform trial protocol that enables the simultaneous evaluation of multiple interventions (i.e., intervention domains) within a consistent infrastructure. Each intervention being evaluated in the MAPT will have an intervention domain protocol that describes additional eligibility criteria, interventions, secondary outcomes, and statistical stopping rules. The overarching objective of the MAPT trial platform is to incrementally decrease decisional uncertainty and identify treatments that will optimize patient outcomes. The platform focuses on the comparative effectiveness of available treatment options.
Adult patients aged 60 years or older with a low-energy minimally displaced femoral neck fracture treated with surgery are eligible for the FASTER-HIP intervention domain. Nearly half of all elderly hip fractures are femoral neck fractures, and approximately 20% are minimally displaced. Internal fixation has remained the treatment of choice for these injuries because these fractures can be fixed in situ, and the surgical implants can be inserted with little surgical dissection. Patients treated with internal fixation experience high complication rates, with the pooled risk of reoperation and mortality each above 14%. Preliminary data have suggested arthroplasty for minimally displaced fractures may lead to better patient outcomes, including improved ambulation, fewer reoperations, and a lower risk of death compared to internal fixation. While the preliminary data supporting the use of arthroplasty for minimally displaced fractures is promising, the necessary evidence to make this practice change remains lacking.
FASTER-HIP is a pragmatic, randomized, open-label, comparative effectiveness trial comparing hip arthroplasty versus internal fixation for minimally displaced femoral neck fractures. Randomization in this domain occurs in a 1:1 ratio (hip arthroplasty:internal fixation). The primary outcome is a composite of death within 120 days, ambulation status at 120 days, and days alive and out of hospital within 120 days of randomization. The primary outcome will be hierarchically assessed using the Win ratio. Secondary outcomes include the same composite at 365 days, individual components of the composite, health-related quality of life (EQ-5D-5L), and pain scores during hospitalization.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Joseph Patterson, MD
- 電話番号:+13234426984
- メール:OrthoTraumaResearch@med.usc.edu
研究場所
-
-
California
-
Irvine、California、アメリカ、92660
- 募集
- University of California, Irvine
-
主任研究者:
- Gerard Slobogean, MD
-
コンタクト:
- Gerard Slobogean, MD
- 電話番号:714-456-1699
- メール:gsloboge@hs.uci.edu
-
Los Angeles、California、アメリカ、90048
- 募集
- Cedars-Sinai Medical Center
-
主任研究者:
- Carol Lin, MD
-
コンタクト:
- Carol Lin, MD
- メール:carol.lin@cshs.org
-
Los Angeles、California、アメリカ、90033
- 募集
- University of Southern California
-
主任研究者:
- Joshua L Gary, MD
-
コンタクト:
- Joshua Gary, MD
- 電話番号:+13234426984
- メール:OrthoTraumaResearch@med.usc.edu
-
Los Angeles、California、アメリカ、90033
- 募集
- Los Angeles General Medical Center
-
主任研究者:
- Joshua L Gary, MD
-
コンタクト:
- Joshua Gary, MD
- 電話番号:+13234426984
- メール:OrthoTraumaResearch@med.usc.edu
-
San Francisco、California、アメリカ、94143
- 募集
- University of California San Francisco
-
主任研究者:
- Saam Morshed, MD
-
コンタクト:
- Saam Morshed, MD
- メール:Saam.morshed@ucsf.edu
-
-
Florida
-
Miami、Florida、アメリカ、33146
- まだ募集していません
- University of Miami
-
コンタクト:
- Giselle Hernandez, MD
- メール:g.hernandez@med.miami.edu
-
主任研究者:
- Giselle Hernandez, MD
-
-
Indiana
-
Bloomington、Indiana、アメリカ、47405
- 募集
- Indiana University
-
主任研究者:
- Dillon O'Neill, MD
-
コンタクト:
- Dillon O'Neill, MD
- メール:doneill5@iuhealth.org
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21201
- 募集
- University of Maryland, Baltimore - R Adams Cowley Shock Trauma Center
-
主任研究者:
- Mark Gage, MD
-
コンタクト:
- Mark Gage, MD
- メール:mgage@som.umaryland.edu
-
Largo、Maryland、アメリカ、20774
- 募集
- University of Maryland Capital Region Health
-
主任研究者:
- Todd Jaeblon, MD
-
コンタクト:
- Todd Jaeblon, MD
- メール:tjaeblon@som.umaryland.edu
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- まだ募集していません
- Beth Israel Deaconess Medical Center
-
コンタクト:
- Ishaq Ibrahim, MD
- メール:ioibrahi@bidmc.harvard.edu
-
主任研究者:
- Ishaq Ibrahim, MD
-
Boston、Massachusetts、アメリカ、02115
- 募集
- Massachusetts General Brigham
-
コンタクト:
- Michael Weaver, MD
- メール:MJWEAVER@BWH.HARVARD.EDU
-
主任研究者:
- Michael Weaver, MD
-
-
Mississippi
-
University、Mississippi、アメリカ、38677
- 募集
- University of Mississippi
-
主任研究者:
- Patrick Bergin, MD
-
コンタクト:
- Patrick Bergin, MD
- メール:pbergin@umc.edu
-
-
New York
-
New York、New York、アメリカ、10016
- 募集
- NYU Langone Health
-
主任研究者:
- Ran Schwarzkopf, MD
-
コンタクト:
- Daniel Waren
- メール:Daniel.waren@nyulangone.org
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45221
- 募集
- University of Cincinnati
-
コンタクト:
- Michael Beltran, MD
- メール:beltrame@ucmail.uc.edu
-
主任研究者:
- Michael Beltran, MD
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- 募集
- University of Oklahoma Health Sciences Center
-
主任研究者:
- Brandon Hull, MD
-
コンタクト:
- Brandon Hull, MD
- メール:Brandon-Hull@ou.edu
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18102
- 募集
- St. Luke's University Health System
-
主任研究者:
- Dustin Greenhill, MD
-
コンタクト:
- Dustin Greenhill, MD
- メール:dustin.greenhill@sluhn.org
-
-
South Carolina
-
Greenville、South Carolina、アメリカ、29601
- 募集
- Prisma Health-Upstate
-
主任研究者:
- Kyle Jeray, MD
-
コンタクト:
- Kyle Jeray, MD
- メール:kyle.jeray@prismahealth.org
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37235
- 募集
- Vanderbilt University
-
コンタクト:
- Lauren Tatman, MD
- メール:lauren.m.tatman@vumc.org
-
主任研究者:
- Lauren Tatman, MD
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84108
- 募集
- University of Utah
-
主任研究者:
- Lucas Marchand, MD
-
コンタクト:
- Lucas Marchand, MD
- メール:lucas.marchand@hsc.utah.edu
-
-
Vermont
-
Burlington、Vermont、アメリカ、05405
- まだ募集していません
- University of Vermont
-
コンタクト:
- Michael Blankstein, MD
- メール:michael.blankstein@uvmhealth.org
-
主任研究者:
- Michael Blankstein, MD
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- 募集
- Inova Health Care Services
-
主任研究者:
- Greg Gaski, MD
-
コンタクト:
- Grag Gaski, MD
- メール:greg.gaski@inova.org
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53706
- 募集
- University of Wisconsin - Madison
-
主任研究者:
- Chris Domes, MD
-
コンタクト:
- Chris Domes, MD
- メール:domes@ortho.wisc.edu
-
-
-
-
-
Edinburgh、イギリス、EH8 8BG
- まだ募集していません
- University of Edinburgh
-
コンタクト:
- Andrew Duckworth, MD
- メール:andrew.duckworth@ed.ac.uk
-
-
-
-
-
Ottawa、カナダ、K1H 8L6
- まだ募集していません
- The Ottawa Hospital
-
コンタクト:
- Bradley Meulenkamp, MD
- メール:bmeulenkamp@toh.ca
-
主任研究者:
- Bradley Meulenkamp, MD
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V6T 1Z4
- 募集
- University of British Columbia
-
コンタクト:
- Aresh Sepehri, MD
-
コンタクト:
-
主任研究者:
- Aresh Sephri, MD
-
Vancouver、British Columbia、カナダ
- 募集
- Fraser Health Authority
-
コンタクト:
- Darius Viskontas, MD
- 電話番号:604-777-5577
- メール:dariusviskontas@yahoo.ca
-
コンタクト:
- 電話番号:604-777-5577
-
主任研究者:
- Darius Viskontas, MD
-
-
Ontario
-
London、Ontario、カナダ、N6A 5W9,
- 募集
- London Health Sciences Centre
-
コンタクト:
- Emil Schemitsch, MD
- メール:emil.schemitsch@lhsc.on.ca
-
主任研究者:
- Emil Schemitsch, MD
-
-
-
-
-
Barcelona、スペイン
- まだ募集していません
- Hospital Universitari Vall d'Hebron
-
コンタクト:
- Carlos Alberto Piedra-Calle, MD
- メール:carlosalberto.piedra@vallhebron.cat
-
主任研究者:
- Carlos Alberto Piedra-Calle, MD
-
Barcelona、スペイン
- まだ募集していません
- Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG)
-
主任研究者:
- Alfred Dealbert, MD
-
コンタクト:
- Alfred Dealbert Dealbert, MD
- メール:adealbert@csapg.cat
-
Barcelona、スペイン、08221
- まだ募集していません
- Hospital Universitario Mutua de Terrassa
-
コンタクト:
- Pablo Castillon Bernal, MD
- メール:pablocastillon@mutuaterrassa.es
-
主任研究者:
- Pablo Castillon Bernal, MD
-
Barcelona、スペイン
- まだ募集していません
- FRCB-IDIBAPS (Hospital Clinic Barcelona)
-
コンタクト:
- Pilar Camacho, MD
- メール:PCAMACHO@clinic.cat
-
主任研究者:
- Pilar Camacho, MD
-
-
-
-
-
Grålum、ノルウェー、1714
- 募集
- Sykehuset Østfold HF / Østfold Hospital Trust
-
コンタクト:
- Frede Frihagen, MD
-
コンタクト:
-
主任研究者:
- Frede Frihagen, MD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 60 years of age or older undergoing surgery due to a minimally displaced femoral neck fracture
- The patient has a health condition affecting physical mobility.
- Complete fracture of the femoral neck (AO/OTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging.
- Minimally displaced fracture that could be, in the judgment of the attending surgeon, managed with either arthroplasty or in situ internal fixation without reduction.
- Low energy injury mechanism.
- Surgeons with expertise in internal fixation and total hip arthroplasty or hemiarthroplasty are available to perform surgery.
Exclusion Criteria:
- The patient is not clinically suitable for either compared treatment.
- Expected injury survival of less than 12 months.
- Terminal illness with expected survival of less than 12 months.
- Incarceration.
- Unable to obtain informed consent due to language barriers.
- Unable to obtain informed consent because the legally authorized representative was unavailable.
- Problems, in the judgment of the study personnel, with maintaining follow-up with the patient.
- Currently enrolled in a study or intervention domain that does not permit co-enrollment.
- Prior enrollment in the specific platform trial intervention domain.
- Patient or legally authorized representative did not provide informed consent (declined participation).
- Eligible patient or legally authorized representative was not approached within the screening window (missed participant).
- Other reasons to exclude the patient, as approved by the data coordinating center.
- Associated lower extremity injury that prevents post-operative weight-bearing.
- Retained hardware around the hip that precludes either study treatment.
- Infection around the hip (soft tissue or bone).
- Pathologic fracture with a lytic lesion in the femoral neck that precludes internal fixation.
- Injury did not occur within 21 days of screening.
- Patient is too ill, in the judgment of the attending surgeon, for internal fixation.
- Patient is too ill, in the judgment of the attending surgeon, for arthroplasty.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:股関節形成術
|
Participants will undergo surgical treatment using standard hip arthroplasty techniques for femoral minimally displaced femoral neck fracture. A modern porous-coated press-fit or cemented hip arthroplasty prosthesis will be used at the treating surgeon's discretion. Press-fit implants that have no ingrowth or ongrowth surface will not be permitted. The type of hip prosthesis (hemiarthroplasty or total hip arthroplasty), bearing (single or dual mobility), or the method of arthroplasty fixation (cemented or uncemented) will be at the discretion of the treating surgeon. |
|
アクティブコンパレータ:内部固定
|
Participants will undergo surgical treatment using standard fixation techniques for minimally displaced femoral neck fractures. The treating surgeon may perform fracture reduction maneuvers if desired. Fixed-angle devices and multiple screws will be permitted. The internal fixation device(s) will be inserted through a small lateral incision. Internal fixation constructs combining cancellous screws and fixed-angle devices will be permitted. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Composite outcome of death, ambulation status, and days alive and out of hospital.
時間枠:120 days after randomization
|
Death consists of time to all-cause mortality. Ambulation will be evaluated using an ordinal ranking of independence. Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
|
120 days after randomization
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Composite outcome of death, ambulation status, and days alive and out of hospital.
時間枠:365 days after randomization
|
Death consists of time to all-cause mortality. Ambulation will be evaluated using an ordinal ranking of independence. Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
|
365 days after randomization
|
|
Death
時間枠:120 days post-randomization
|
Death consists of time to all-cause mortality. |
120 days post-randomization
|
|
Death
時間枠:12 months post-randomization
|
Death consists of time to all-cause mortality. |
12 months post-randomization
|
|
Ambulation status
時間枠:120 days post-randomization
|
Ambulation will be evaluated using an ordinal ranking of independence |
120 days post-randomization
|
|
Ambulation status
時間枠:12 months post-randomization
|
Ambulation will be evaluated using an ordinal ranking of independence |
12 months post-randomization
|
|
Days alive and out of hospital
時間枠:120 days post-randomization
|
Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
|
120 days post-randomization
|
|
Days alive and out of hospital
時間枠:12 months post-randomization
|
Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
|
12 months post-randomization
|
|
Health-related quality of life
時間枠:120 days days post-randomization
|
EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health |
120 days days post-randomization
|
|
Health-related quality of life
時間枠:12 months post-randomization
|
EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health |
12 months post-randomization
|
|
Numeric Pain Rating Scale
時間枠:During hospitalization in the first seven postoperative days
|
The highest level of pain recorded daily in the participant's medical record - Range: 0-10, higher score indicates higher level of pain |
During hospitalization in the first seven postoperative days
|
協力者と研究者
協力者
捜査官
- 主任研究者:Joseph T Patterson, MD、University of Southern California
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- BPS-2024C1-37436
- BPS-2024C1-37436 (その他の助成金/資金番号:Patient-Centered Outcomes Research Institute)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。